Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

385291

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Skin Cancer
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what guidelines are issued to Clinical Commissioning Groups regarding patients with high-risk skin cancers such as melanoma.
tabling member printed	Lord Clark of Windermere
uin	HL774
answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>NHS England has published a service specification for adult skin cancer services that sets out what the National Health Service must have in place to offer high quality skin cancer treatment, care and support. Embedded in this is the current best practice guidance on skin cancer published by the National Institute for Health and Care Excellence (NICE).</p><p> </p><p> </p><p> </p><p>NICE is developing a guideline on the assessment and management of melanoma. NICE currently expects to publish its final guidance in July 2015. Further information is available at the following link and a copy of the webpage has been attached.</p><p> </p><p> </p><p> </p><p><a href="http://www.nice.org.uk/guidance/indevelopment/gid-cgwave0674" target="_blank">www.nice.org.uk/guidance/indevelopment/gid-cgwave0674</a></p><p> </p><p> </p><p> </p><p>In addition, NICE is currently in the process of updating its Public Health guidance on skin cancer prevention: information, resources and environmental changes (PH32).</p><p> </p> answering member printed Lord Prior of Brampton question first answered 08/07/2015 13:52:29 answering member 127 label Biography information for Lord Prior of Brampton attachment 1 file name NICE webpage.pdf title NICE webpage
tabling member	525 label Biography information for Lord Clark of Windermere

385293

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what is the total value of projected savings to be made by removing drugs and indications from the Cancer Drugs Fund in England over (1) Q1 of 2015–16, and (2) the whole of 2015–16.
tabling member printed	Lord Hunt of Kings Heath
uin	HL776
answer	answer is ministerial correction date of answer 02/07/2015 answer text <p> </p><p /> <p>NHS England has advised that the projected value of savings from the Cancer Drugs Fund, as a result of removing drugs from the national list, is not yet available.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>Decisions to de-list drugs were made taking account of the need to ensure the limited resources of the Fund are used most effectively. Advances in medical science mean that new and exciting cancer medicines are emerging all the time and we want people to have access to these too.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>The Government established the Cancer Drugs Fund to ensure that cancer patients in England have better access to life-extending and improving drugs not routinely funded by the National Health Service.</p><p /> <p> </p><p /> <p> </p><p /> <p> </p><p /> <p>Between October 2010 and March 2015, the Fund has helped over 72,000 cancer patients.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 02/07/2015 15:54:13 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385294

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what assessment they have made of the impact of delisting from the Cancer Drugs Fund on the availability of cancer drugs in the United Kingdom, in comparison with (1) the level of access in 2010 when the Fund was introduced, and (2) availability levels in comparable European countries.
tabling member printed	Lord Hunt of Kings Heath
uin	HL777
answer	answer is ministerial correction date of answer 02/07/2015 answer text <p>Neither the Department nor NHS England has made any such assessment.</p><p> </p><p> </p><p> </p><p>Decisions to de-list drugs were made taking account of the need to ensure the limited resources of the Fund are used most effectively. Advances in medical science mean that new and exciting cancer medicines are emerging all the time and we want people to have access to these too.</p><p> </p><p> </p><p> </p><p>The Government established the Cancer Drugs Fund to ensure that cancer patients in England have better access to life-extending and improving drugs not routinely funded by the NHS.</p><p> </p><p> </p><p> </p><p>Between October 2010 and March 2015, the Fund has helped over 72,000 cancer patients.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 02/07/2015 15:55:02 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385295

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Commissioning Groups
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government what action they plan to take in the event of the Clinical Commissioning Groups outsourcing parts of their commissioning role to get round the restrictions on administrative costs.
tabling member printed	Lord Hunt of Kings Heath
uin	HL778
answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>Clinical commissioning groups (CCGs), as independent statutory bodies, can choose how best to carry out their commissioning functions from within their running cost budget.</p><p> </p><p> </p><p> </p><p>Where CCGs choose to outsource their support and to buy from external providers, this funding will be charged against their fixed running cost allowance.</p><p> </p><p> </p><p> </p><p>Service integrators and lead providers co-ordinate and provide care for patients; they are not commissioners, nor do they undertake commissioning activities or responsibilities.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL779 HL780 question first answered 29/06/2015 15:05:34 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385296

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Commissioning Groups
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government, when Clinical Commissioning Groups outsource some of their commissioning role to integrators, lead providers or through other similar mechanisms, how the administrative costs so transferred will be counted against the Clinical Commissioning Groups' administrative cost cap.
tabling member printed	Lord Hunt of Kings Heath
uin	HL779
answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>Clinical commissioning groups (CCGs), as independent statutory bodies, can choose how best to carry out their commissioning functions from within their running cost budget.</p><p> </p><p> </p><p> </p><p>Where CCGs choose to outsource their support and to buy from external providers, this funding will be charged against their fixed running cost allowance.</p><p> </p><p> </p><p> </p><p>Service integrators and lead providers co-ordinate and provide care for patients; they are not commissioners, nor do they undertake commissioning activities or responsibilities.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL778 HL780 question first answered 29/06/2015 15:05:33 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385297

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Clinical Commissioning Groups
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether, when Clinical Commissioning Groups outsource some of their commissioning role, the element of administration that would have counted towards the fixed cap on administrative costs will be separately identified and appropriately deducted from Clinical Commissioning Group budgets.
tabling member printed	Lord Hunt of Kings Heath
uin	HL780
answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>Clinical commissioning groups (CCGs), as independent statutory bodies, can choose how best to carry out their commissioning functions from within their running cost budget.</p><p> </p><p> </p><p> </p><p>Where CCGs choose to outsource their support and to buy from external providers, this funding will be charged against their fixed running cost allowance.</p><p> </p><p> </p><p> </p><p>Service integrators and lead providers co-ordinate and provide care for patients; they are not commissioners, nor do they undertake commissioning activities or responsibilities.</p><p> </p> answering member printed Lord Prior of Brampton grouped question UIN HL778 HL779 question first answered 29/06/2015 15:05:34 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	2024 label Biography information for Lord Hunt of Kings Heath

385300

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Liver Diseases
house id	2
legislature	25277 pref label House of Lords
question text	To ask Her Majesty’s Government whether the programme of work for liver disease being developed by Public Health England will include a hepatitis C improvement framework.
tabling member printed	Baroness Masham of Ilton
uin	HL783
answer	answer is ministerial correction date of answer 08/07/2015 answer text <p>NHS England and Public Health England (PHE) are working alongside a coalition of other organisations and patient groups to draft a framework for hepatitis C improvement. This hepatitis C improvement framework will set high level aims for the public health system towards elimination of hepatitis C related liver disease as a significant public health concern.</p><p> </p><p> </p><p> </p><p>The hepatitis C improvement framework will be referred to in PHE’s liver disease framework.</p><p> </p> answering member printed Lord Prior of Brampton question first answered 08/07/2015 14:54:40 answering member 127 label Biography information for Lord Prior of Brampton
tabling member	1850 label Biography information for Baroness Masham of Ilton

385346

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dementia: Research
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will make it his policy to prioritise research on dementia during this Parliament.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	3985
answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>As part of the Challenge on Dementia 2020, the National Institute for Health Research, the Medical Research Council, and the Economic and Social Research Council will maintain their current collective spend on dementia research of over £60 million a year. Research spending has already doubled from a baseline of £28.2 million in 2009/10.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 29/06/2015 16:00:20 answering member 4020 label Biography information for George Freeman
tabling member	1409 label Biography information for Mr Gregory Campbell

385347

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Stem Cells: Donors
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what plans his Department has for the funding of the UK stem cell donor register and cord blood programme over the next five years.
tabling member constituency	East Londonderry
tabling member printed	Mr Gregory Campbell
uin	3986
answer	answer is ministerial correction date of answer 29/06/2015 answer text <p>Since 2011, the Department has provided our delivery partners, NHS Blood and Transplant and Anthony Nolan, a total of £16 million in additional, new funding to improve stem cell transplantation services in the United Kingdom. Further funding of £3 million has already been confirmed for 2015-16. Budgets for 2016-17 will be determined following the next Spending Review.</p><p> </p><p> </p><p> </p><p>This funding already provided has led to a tangible improvement in the availability of stem cells in the UK and the achievements include:</p><p> </p><p> </p><p> </p><p>- More UK patients received a stem cell transplant in 2014 than ever before.</p><p> </p><p>- Over 60% of black, Asian and minority ethnic (BAME) patients are now able to find a well matched donor compared to only 40% in 2010.</p><p> </p><p>- A single unified bone marrow donor registry has been created streamlining the provision of stem cells and reducing the time to provide cells from adult donors.</p><p> </p><p>- The proportion of patients receiving cord blood from UK donors has significantly increased.</p><p> </p><p>- The increased use of UK-sourced stem cells has meant that more donors than ever are available to donate leading to a significant cost saving by reducing the need to import stem cells.</p><p> </p><p> </p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 29/06/2015 16:14:07 answering member 3918 label Biography information for Jane Ellison
tabling member	1409 label Biography information for Mr Gregory Campbell

385353

registered interest
date	24/06/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Livestock: Antibiotics
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to address the effect of the overuse of antibiotics in farms animals.
tabling member constituency	Blaydon
tabling member printed	Mr David Anderson
uin	4177
answer	answer is ministerial correction date of answer 03/07/2015 answer text <p>Tackling the inappropriate use of antibiotics in both humans and animals is a key part of the UK Five Year Antimicrobial Resistance Strategy 2013-18, which was developed by the Department of Health jointly with the Department for Environment, Food and Rural Affairs (Defra) and the Veterinary Medicines Directorate (VMD).</p><p> </p><p> </p><p> </p><p>Oversight of the implementation of the UK Strategy is the responsibility of the High Level Steering Group which is chaired by a senior Department of Health official and includes representatives from both Defra and VMD. The Steering Group produced an annual report and implementation plan in December 2014. This plan includes steps to reduce antibiotic usage in livestock production in real terms over the next four years. The document is available at:</p><p> </p><p> </p><p> </p><p><a href="https://www.gov.uk/government/publications/progress-report-on-the-uk-five-year-amr-strategy-2014" target="_blank">https://www.gov.uk/government/publications/progress-report-on-the-uk-five-year-amr-strategy-2014</a></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 03/07/2015 11:46:57 answering member 3918 label Biography information for Jane Ellison
tabling member	1486 label Biography information for Mr David Anderson